Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
2024年5月23日 - 10:05PM
A number of accomplished medical and scientific experts presented
critical new research on sleep conditions and their effect on
cardiovascular health at the American Thoracic Society
International Conference. The ResMed-supported research provided
new insights into the effectiveness of PAP therapy in treating
sleep-disordered breathing and its associated clinical benefits.
The studies were among 26 supported by ResMed (NYSE: RMD, ASX: RMD)
in collaboration with leading scientists including Michael Arzt,
MD, Universitätsklinikum Regensburg, Germany; Jean-Louis Pépin, MD,
Grenoble Alpes University, France; Atul Malhotra, MD, University of
California, San Diego; and Holger Woehrle, Ulm Lung Centre,
Germany.
Real-world Trends of Glucagon-Like Peptide-1 (GLP-1)
Receptor Agonists and PAP Therapy Use in OSAWith growing
attention on the use of anti-obesity medications, such as GLP-1s in
clinical practice, a timely study was presented by Dr. Atul
Malhotra which explored the real-world relationship of GLP-1
medication use and PAP therapy in patients with OSA. The use of
GLP-1s did not lead to higher discontinuation rates of PAP therapy,
rather this analysis found that patients who were adherent to their
GLP-1 medication had higher levels of PAP therapy use than those
who were non-adherent to their GLP-1 medication.
PAP Therapy Continues to Lower Risks Associated with
Sleep DisordersSeveral studies demonstrated findings
showing continued effectiveness of PAP therapies for patients with
sleep disorder conditions like obstructive sleep apnea. Among these
was an analysis of data from 27 randomized control trials and
non-randomized control studies on the effects of PAP on patients
with OSA. This meta-study, presented by Dr. Atul Malhotra, found
mortality was 37% lower on average in patients with PAP-treated OSA
vs untreated OSA.
An additional study, presented by German physician and sleep
researcher Holger Woehrle, looked at 17,000 treatment-naïve
patients in both PAP-treated and untreated cohorts and showed PAP
treatment reduces hospitalization in patients with OSA over the
first four years of treatment. This finding demonstrates a
correlation between the use of PAP therapy and a reduction in use
of healthcare resources.
Examining the Prevalence of Obstructive Sleep Apnea in
the United StatesA study presented by ResMed’s research
scientist Elroy Boers projected an increase in OSA cases in the
United States using patient data calibrated across subgroups of
age, sex and body-mass index (BMI). According to this research, due
to the growing and aging population in the United States as well as
increased BMI trends, the already substantial burden of OSA is
expected to increase by 27.6% by 2050 in men and women aged 30-70,
with an overall prevalence within this group projected to be 26%.
As OSA continues to increase, reliance on PAP therapy will rise as
it remains the gold standard for treatment.
Adaptive Servo-Ventilation Patients with Treatment
Emergent or Persistent Central Sleep Apnea (TE-CSA) and Central
Sleep Apnea induced by Opioid UseTwo studies evaluated the
effects of Adaptive Servo-Ventilation (ASV) therapy in two
populations, patients with TE-CSA and patients on long-term opioid
therapy. The former, presented by German physician and sleep
researcher Dr. Michael Arzt, demonstrated ASV therapy showed a
reduced symptom burden and an improvement in quality of life for
patients with TE-CSA, with or without comorbid cardiovascular
disease*, a comorbidity present in a majority of patients with
TE-CSA.
The second study, presented by French physician and researcher
Dr. Jean-Louis Pépin, studied 86 CSA patients on long-term opioid
therapy and who used ASV treatments for at least one year. This
study showed a -1 median reduction in Epworth Sleepiness Scale
(ESS) values and a median increase of .96 on the Functional
Outcomes of Sleep Questionnaire (FOSQ), demonstrating a lower
symptom burden and improved quality of life.
Reducing Risk of Death in COPD Patients with
Non-Invasive Ventilation (NIV) at HomeAnother study, also
presented by Dr. Jean-Louis Pépin, looked at nearly 50,000 adults
with COPD who were treated via domiciliary NIV. The study showed
long-term home use of NIV was strongly associated with a reduced
risk of death.
“The host of critical research presented by influential and
accomplished experts at ATS continues to show the effectiveness and
importance of PAP in treating sleep disordered breathing and
limiting their impact on adverse health effects,” said Carlos M.
Nunez, MD, Chief Medical Officer at ResMed. “The increasing
prevalence of cardiovascular conditions, obesity and an aging
population in the United States demonstrate why increasing
awareness of sleep health and conducting research into how best to
improve sleep quality and overall health outcomes is so critical
today.”
In addition to the ResMed-supported abstracts, Dr. Nunez served
as a panelist at two ATS sessions: The Healthcare of Today, Looking
Towards Tomorrow: Digital Innovations and Patient Centricity, which
examined the imperative for investing in digital health and driving
innovations for personalized patient experiences, as well as
Enabled Clinicians, Enhanced Care: Best Practices for Leveraging
Digital Health Solutions, which showcased how digital health
solutions and digital therapeutics can find a place in today’s
clinical workflows.
*ASV therapy is contraindicated in patients with chronic,
symptomatic heart failure (NYHA 2-4) with reduced left ventricular
ejection fraction (LVEF ≤ 45%) and moderate to severe predominant
central sleep apnea.
The complete list of ResMed-sponsored studies presented
at ATS 2024 include:
- Treatment of sleep-disordered breathing with adaptive
servo-ventilation (READ-ASV) in opioid users – a European
Registry
- 8-year Trends in Obesity, Type 2 Diabetes, and Glucagon-like
Peptide-1 (GLP-1) Use in Patients with Obstructive Sleep Apnea
- Impact of CPAP Termination on Permanent Work Disability in
Obstructive Sleep Apnea: A French Nationwide Alaska Database
Analysis
- Tailoring Social Support to Improve PAP Therapy Usage in
Obstructive Sleep Apnea
- Examining Alignment of Patient Medication-taking Behaviors with
Inhaler Usage Recommendations in Chronic Obstructive Pulmonary
Disease and Asthma
- Using Natural Language Processing for Qualitative Research:
Insights from a Real-world Analysis
- A Qualitative Analysis of Perceptions and Awareness of Air
Pollution and Its Health Effects in Asthma Among Asthma-care
Professionals Across Southern California
- An Estimate of the Prevalence of Obstructive Sleep Apnea in the
United States Into 2050
- All-cause Mortality in Obstructive Sleep Apnea: Systematic
Literature Review Including Randomized Trials and Confounding
Adjusted Non-Randomized Controlled Studies and Meta-analysis of
Positive Airway Pressure Treatment
- Impact of Positive Airway Pressure (PAP) Therapy on
Hospitalization in Obstructive Sleep Apnea (OSA): Analysis of a
German Healthcare Database
- Hypoxic Burden but Not AHI Predicts Risk of Cardiovascular
Events: A Secondary Analysis of the RICCADSA Clinical Trial
- A Digital Quality Improvement Program Delivered by Clinical
Pharmacists Can Reduce Acute Care Visits In COPD
- Hands-on Simulation Training with Home Ventilators Improves
PCCM Fellow Understanding of Nocturnal NIV in Chronic
Hypercapnia
- The Economic and Health Burden of COPD in North America Through
2050: A Scenario Analysis Based on Two Large Data Sources
- Impact of long-term domiciliary noninvasive ventilation (NIV)
on severe exacerbations and survival in Patients with Chronic
Obstructive Pulmonary Disease (COPD): a nationwide cohort study
using multistate models
- Nocturnal Hypoxemic Burden and Micro- and Macrovascular Disease
in Patients with Type 2 Diabetes
- Risk Factors for Severe Exacerbation Occurrence Among Patients
With COPD-OSA Overlap Syndrome Using Bilevel Positive Airway
Pressure Therapy
- Adherence to Glucagon-like Peptide-1 Receptor Agonists (GLP-1s)
in Obstructive Sleep Apnea Patients with and Without Type 2
Diabetes
- Treatment of sleep-disordered breathing with adaptive
servo-ventilation (READ-ASV) – outcomes in patients with
treatment-emergent or persistent central sleep apnea (TE-CSA) in a
European Registry
- A Scenario-based Modeling Study to Project the Future Burden of
COPD in the United States Accounting for the Effects of
E-cigarettes
- The Impact of Weight Change on Positive Airway Pressure Use In
Patients With Obstructive Sleep Apnea And Obesity
- Real World GLP-1 Adherence in Patients with Treated Obstructive
Sleep Apnea
- Less REM Sleep Predicts Mortality in Adults with Coronary
Artery Disease and Obstructive Sleep Apnea: The RICCADSA Trial
- Gender Specific Differences in a National Sample of Individuals
with Comorbid Insomnia, Obstructive Sleep Apnea (OSA), and
Depression
- Use of Weight Management Regimens Among Positive Airway
Pressure-Treated Patients with Obstructive Sleep Apnea and
Obesity
- A Mixed-methods Exploration of Patient Perspectives on Pap
Therapy Initiation: Implications for Improved Outreach and
Education
About ResMed At ResMed (NYSE: RMD, ASX: RMD) we
pioneer innovative solutions that treat and keep people out of the
hospital, empowering them to live healthier, higher-quality lives.
Our digital health technologies and cloud-connected medical devices
transform care for people with sleep apnea, COPD, and other chronic
diseases. Our comprehensive out-of-hospital software platforms
support the professionals and caregivers who help people stay
healthy in the home or care setting of their choice. By enabling
better care, we improve quality of life, reduce the impact of
chronic disease, and lower costs for consumers and healthcare
systems in more than 140 countries. To learn more, visit
ResMed.com and follow @ResMed.
For Media
Peter Duckler
pduckler@realchemistry.com
Rowena Kelley
news@resmed.com
For Investors
Amy Wakeham
investorrelations@resmed.com
ResMed (NYSE:RMD)
過去 株価チャート
から 8 2024 まで 9 2024
ResMed (NYSE:RMD)
過去 株価チャート
から 9 2023 まで 9 2024